Navigation Links
Oncothyreon files investigational new drug application for PX-866 oncology compound
Date:5/1/2008

BELLEVUE, WA, May 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for PX-866, a small molecule phosphatidylinositol-3-kinase (PI-3-kinase) inhibitor for the treatment of advanced cancers. Following FDA review, Oncothyreon plans to initiate a Phase 1 clinical trial of PX-866.

"PX-866 is a potent inhibitor of phosphatidylinositol-3-kinase that has demonstrated preclinical anti-tumor activity in models of human ovarian cancer, lung cancer and intracranial glioblastoma," said Lynn Kirkpatrick, Ph.D., Chief Scientific Officer of Oncothyreon. "We believe that PX-866, an irreversible inhibitor of the kinase, will have dose and schedule advantages that may position it well in the current field of PI-3-kinase inhibitors."

"This IND for PX-866 demonstrates the continued advancement of Oncothyreon's small molecule oncology pipeline," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. In addition to the planned trial of PX-866, Oncothyreon is currently conducting a Phase 2 trial of PX-12, a small molecule inhibitor of thioredoxin-1, in patients with advanced pancreatic cancer and a Phase 1 trial of PX-478, a small molecule inhibitor of HIF-1 alpha, in patients with advanced solid tumors or lymphomas.

About PX-866

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Aberrant activation and regulation of PI-3 kinase is implicated in a large proportion of human cancers including breast, glioma, colon, ovarian, prostate and melanoma, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). PX-866 has been shown to induce prolonged inhibition of tumor PI-3 kinase signaling following both oral and intravenous administration. The compound has been shown to have goo
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
3. Oncothyreon announces effectiveness of shelf registration statement
4. Oncothyreon announces issuance of patent for PX-867
5. Oncothyreon to present at upcoming investment conferences
6. Oncothyreon reports full year and fourth quarter 2007 financial results
7. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
8. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
9. Oncothyreon launches new corporate website
10. Oncothyreon to present at BIO CEO & Investor Conference
11. Oncothyreon highlights corporate and clinical objectives for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...
(Date:12/11/2009)... OSLO, December 11 Algeta ASA ... the first clinical center in the,US, the ... randomizing patients,in the phase III clinical study ... as hormone-refractory) prostate cancer,(CRPC) that has metastasized ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate ...
(Date:12/11/2009)... 11, 2009 -- Esco announces the opening of a NEW 2nd ... a technical service, training and logistics center to support Esco,s growth ... Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... of a NEW 2nd North American facility in Marietta, OH. The ...
(Date:12/10/2009)... Eye Institute (NEI), a division of the National Institutes of ... to help fund its development of a non-invasive, passive diffusion-based ... ... Salt Lake City, UT (PRWEB) December 10, ... the National Institutes of Health (NIH), awarded a $2.18 million ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3
... Company,s Global Branding Strategy, ST. LOUIS, April ... integration of its Riedel-de Haen(R),Laboratory Reagents into its ... )., "We have created a strong international ... Global Vice President of Marketing and,Sales for the ...
... of bluetongue Bovilis BTV8 vaccine released to supply Northern ... ... Health (NYSE: SGP ) released the first batch,of Bovilis BTV8 ... combining after the acquisition in 2007 the,strength of Intervet and Schering-Plough ...
... John C. Lechleiter,Ph.D., president and CEO of Eli ... the,Bay State for its investment in biotechnology and ... a roadmap for ensuring the state,s significant,investment is ... Biz/Bio,Conference, a gathering of policymakers, business leaders and ...
Other Biology Technology:Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 2Intervet/Schering-Plough Animal Health Outlines Strength of the Combination 3Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs 2Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs 3
(Date:12/13/2009)... Haven, Conn.A team led by Yale University researchers ... whole blood for the first time. Their findings, ... publication of Nature Nanotechnology , could dramatically ... cancer and other diseases. , The ... of Engineering & Applied Science, and Tarek Fahmy, ...
(Date:12/13/2009)... CADecember 10, 2009Researchers at The Scripps Research Institute ... single protein from an ancient family of enzymes ... body. In addition to providing guidance for understanding ... a theoretical underpinning for the protein,s possible use ... , The research was published in the December ...
(Date:12/11/2009)... demand for premium fruit increases, growers are being ... And to boost their bottom line, orchard owners ... fruit quality while reducing labor costs. , Hand ... produce larger, healthier fruit, is among the most ... on fruit production overhead, and, ultimately, prices paid ...
Breaking Biology News(10 mins):Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3Horizontal string trimmer reduces labor costs, increases peach size 2AMT Successful in Preclinical Treatment of DMD 14791 1AMT Successful in Preclinical Treatment of DMD 14791 2AMT Successful in Preclinical Treatment of DMD 14791 3Teamsters Look to Darden Restaurant Group for Justice 61104 1Teamsters Look to Darden Restaurant Group for Justice 61104 2Sutter Medical Center Receives Certification to Use Ventricular Assist Devices as Destination Therapy 6151 1Sutter Medical Center Receives Certification to Use Ventricular Assist Devices as Destination Therapy 6151 2
... stem nematode, and fungi, such as white rot, are ... cause rot. Soil samples are investigated to detect this; ... for Nematology (University of Wageningen) the company Blgg has ... and white rot in soil samples. , Agricultural ...
... Intelligent Design theorists have in America be broken by ... makes the case for Darwin in The Annual Robert ... lines of America's struggle over evolution", at the Grant ... 16th November. , In his public lecture, Professor Ruse, ...
... new study examines the origins of holiday giving and ... , "Reciprocity is arguably the foundational basis of ... ?Santa Barbara). "A core feature of reciprocity is the ... social partners. Contingency is important because it sets the ...
Other Biology News:DNA technique measures suitability of soil for onion crops 2'Creationism is not science' ?making the case for Darwin at UCL 2
Recombinant Equine IL-6...
... provide two highly efficient methods of identifying ... preparation. By using the large-scale screen method ... do is to transfer partial colonies of ... plates into the solutions provided by the ...
... N. Fernandez and G. Butcher (1998). ... subject of much research in the immunology ... structure of MHC proteins and in their ... are now faced with the prospect of ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: